Radiotherapy in Geriatric Gastrointestinal Cancer Patients

radyasyon_onkolojisi_102

Ertuğrul TEKÇEa , Züleyha AKGÜNb,c
aAcıbadem Mehmet Ali Aydınlar University Atakent Hospital, Department of Radiation Oncology, İstanbul, Türkiye
bÜsküdar University Faculty of Medicine, Department of Radiation Oncology, İstanbul, Türkiye
cMemorial Şişli Hospital, Clinic of Radiation Oncology, İstanbul, Türkiye

Tekçe E, Akgün Z. Radiotherapy in geriatric gastrointestinal cancer patients. In: Metcalfe E, ed. Radiotherapy and Current Developments in Geriatric Cancers. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.33-40.

ABSTRACT
As life expectancy increases, gastrointestinal (GI) cancer management becomes increasingly important in older individuals. Due to the increased surgical risks of elderly patients, studies are being conducted on alternative treatment methods such as radiotherapy (RT) or chemoradiotherapy (CRT). Although clinical trials are limited, observational data suggest that RT is effective and safe in this patient group. Advances in radiation oncology allow for the use of milder treatment options, even in elderly or frail individuals, while reducing side effects. Therefore, the treatment decision should be based not only on age but also on the general condition of the patient and the severity of concomitant diseases. Careful evaluation of geriatric patients plays a critical role in determining the most appropriate treatment method.

Keywords: Geriatrics; gastrointestinal neoplasms; radiotherapy; aged

Referanslar

  1. Enzinger PC, Mayer RJ. Gastrointestinal cancer in older patients. Seminars in oncology. 2004;31(2):206-19. [Crossref]  [PubMed]
  2. Schlesinger-Raab A, Werner J, Friess H, Holzel D, Engel J. Age and Outcome in Gastrointestinal Cancers: A Population-Based Evaluation of Oesophageal, Gastric and Colorectal Cancer. Visceral medicine. 2017;33(4):245-53. [Crossref]  [PubMed]  [PMC]
  3. Hershman DL, Wright JD. Comparative effectiveness research in oncology methodology: observational data. Journal of Clinical Oncology: official American Society of Clinical Oncology journal. 2012;30(34):4215-22. [Crossref]  [PubMed]
  4. Roeder F, Jensen AD, Lindel K, Mattke M, Wolf F, Gerum S. Geriatric Radiation Oncology: What We Know and What Can We Do Better? Clinical interventions in aging. 2023;18:689-711. [Crossref]  [PubMed]  [PMC]
  5. Global Burden of Disease Cancer C, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The Global Burden of Cancer 2013. JAMA Oncology. 2015;1(4):505-27. [Crossref]  [PubMed]  [PMC]
  6. Ishii N, Uchida S, Itoh T, Horiki N, Matsuda M, Setoyama T, et al. Endoscopic submucosal dissection with a combination of small-caliber-tip transparent hood and flex knife for superficial esophageal neoplasia. Is it safe for elderly patients? Surgical endoscopy. 2010;24(9):2110-9. [Crossref]  [PubMed]
  7. Minashi K, Nihei K, Mizusawa J, Takizawa K, Yano T, Ezoe Y, et al. Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology. 2019;157(2):382-90. [Crossref]  [PubMed]
  8. Bostel T, Akbaba S, Wollschläger D, Mayer A, Nikolaidou E, Murnik M, et al. Chemoradiotherapy in geriatric patients with squamous cell carcinoma of the esophagus: Multi-center analysis on the value of standard treatment in the elderly. Front Oncol. 2023;13:1063670. [Crossref]  [PubMed]  [PMC]
  9. Kato K, Ito Y, Nozaki I, Daiko H, Kojima T, Yano M, et al. Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology. 2021;161(6):1878-86. [Crossref]  [PubMed]
  10. Tanisada K, Teshima T, Ikeda H, Abe M, Owen JB, Hanks GE, et al. A preliminary outcome analysis of the Patterns of Care Study in Japan for esophageal cancer patients with special reference to age: nonsurgery group. International Journal of Radiation Oncology, Biology, Physics. 2000;46(5):1223-33. [Crossref]  [PubMed]
  11. Tougeron D, Hamidou H, Scotte M, Di Fiore F, Antonietti M, Paillot B, et al. Esophageal cancer in the elderly: an analysis of the factors associated with treatment decisions and outcomes. BMC Cancer. 2010;10:510. [Crossref]  [PubMed]  [PMC]
  12. Suzuki G, Yamazaki H, Aibe N, Masui K, Kimoto T, Shimizu D, et al. Definitive Radiotherapy for Older Patients Aged >/=75 Years With Localized Esophageal Cancer. In Vivo. 2019;33(3):925-32. [Crossref]  [PubMed]  [PMC]
  13. Li X, Zhao LJ, Liu NB, Zhang WC, Pang QS, Wang P, et al. Feasibility and efficacy of concurrent chemoradiotherapy in elderly patients with esophageal squamous cell carcinoma: a respective study of 116 cases from a single institution. Asian Pacific journal of cancer prevention: APJCP. 2015;16(4):1463-9. [Crossref]  [PubMed]
  14. Zhao L, Zhou Y, Pan H, Yin Y, Chai G, Mu Y, et al. Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients. Journal of Cancer. 2017;8(16):3242-50. [Crossref]  [PubMed]  [PMC]
  15. Lester SC, Lin SH, Chuong M, Bhooshan N, Liao Z, Arnett AL, et al. A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. International Journal of Radiation Oncology, Biology, Physics. 2017;98(4):820-8. [Crossref]  [PubMed]
  16. Bostel T, Nikolaidou E, Wollschlager D, Mayer A, Kaufmann J, Hopprich A, et al. Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junction. Radiation Oncology. 2024;19(1):28. [Crossref]  [PubMed]  [PMC]
  17. Servagi Vernat S, Guilbert P, Bouche G, Ramiandrisoa F, Bellefqih S. [Hypofractionated radiotherapy in rectal cancer for elderly patients]. Cancer Radiotherapie: Journal de la Societe Francaise de Radiotherapie Oncologique. 2018;22(6-7):644-6. [Crossref]  [PubMed]
  18. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394-424. [Crossref]  [PubMed]
  19. Saif MW, Makrilia N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly: an overview. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2010;36(8):709-17. [Crossref]  [PubMed]
  20. Schendel J, Jost E, Mah M, Mack L, McCall M, Gu N, et al. Gastric cancer management in elderly patients: a population-based study of treatment patterns and outcomes in gastric cancer patients >/= 75 years from Alberta, Canada. American Journal of Surgery. 2021;221(4):839-43. [Crossref]  [PubMed]
  21. Yang SP, Tan LL, Zhou P, Lian CL, Wu SG, He ZY. The addition of radiotherapy to breast-conserving surgery improves survival for elderly patients with early breast cancer. Frontiers in Oncology. 2022;12:917054. [Crossref]  [PubMed]  [PMC]
  22. Wang X, Zhao J, Fairweather M, Yang T, Sun Y, Wang J. Optimal treatment for elderly patients with resectable proximal gastric carcinoma: a real-world study based on National Cancer Database. BMC Cancer. 2019;19(1):1079. [Crossref]  [PubMed]  [PMC]
  23. Merchant SJ, Kong W, Mahmud A, Booth CM, Hanna TP. Palliative Radiotherapy for Esophageal and Gastric Cancer: Population-Based Patterns of Utilization and Outcomes in Ontario, Canada. Journal of Palliative Care. 2023;38(2):157-66. [Crossref]  [PubMed]  [PMC]
  24. Tey J, Zheng H, Soon YY, Leong CN, Koh WY, Lim K, et al. Palliative radiotherapy in symptomatic locally advanced gastric cancer: A phase II trial. Cancer Medicine. 2019;8(4):1447-58. [Crossref]  [PubMed]  [PMC]
  25. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136(5):E359-86. [Crossref]  [PubMed]
  26. Gilabert M, Raoul JL, Rousseau F. How to treat pancreatic adenocarcinoma in the elderly: How far can we go in 2017? Journal of Geriatric Oncology. 2017;8(6):407-12. [Crossref]  [PubMed]
  27. Le Scodan R, Mornex F, Girard N, Mercier C, Valette PJ, Ychou M, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation, prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Annals of Oncology: official journal of the European Society for Medical Oncology. 2009;20(8):1387-96. [Crossref]  [PubMed]
  28. Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. Journal of clinical oncology: Official Journal of the American Society of Clinical Oncology. 2020;38(16):1763-73. [Crossref]  [PubMed]  [PMC]
  29. Oziel-Taieb S, Faure M, Gilabert M, Autret A, Turrini O, Moureau-Zabotto L, et al. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. Journal of Gastrointestinal Cancer. 2016;47(1):15-9. [Crossref]  [PubMed]
  30. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU, and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Annals of Oncology: official journal of the European Society for Medical Oncology. 2008;19(9):1592-9. [Crossref]  [PubMed]
  31. Frakes J, Mellon EA, Springett GM, Hodul P, Malafa MP, Fulp WJ, et al. Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy. Journal of Gastrointestinal Oncology. 2017;8(5):758-65. [Crossref]  [PubMed]  [PMC]
  32. Iwai T, Yoshimura M, Ashida R, Goto Y, Kishi T, Itasaka S, et al. Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma. Radiation Oncology. 2020;15(1):264. [Crossref]  [PubMed]  [PMC]
  33. Herman JM, Chang DT, Goodman KA, Dholakia AS, Raman SP, Hacker-Prietz A, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121(7):1128-37. [Crossref]  [PubMed]  [PMC]
  34. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. International Journal of Radiation Oncology, Biology, Physics. 2008;72(3):678-86. [Crossref]  [PubMed]
  35. Tchelebi LT, Lehrer EJ, Trifiletti DM, Sharma NK, Gusani NJ, Crane CH, et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis. Cancer. 2020;126(10):2120-31. [Crossref]  [PubMed]
  36. Kim CH, Ling DC, Wegner RE, Flickinger JC, Heron DE, Zeh H, et al. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Radiation Oncology. 2013;8:240. [Crossref]  [PubMed]  [PMC]
  37. Bryant JM, Palm RF, Herrera R, Rubens M, Hoffe SE, Kim DW, et al. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART). Cancer control: Journal of the Moffitt Cancer Center. 2023;30:10732748221150228. [Crossref]  [PubMed]  [PMC]
  38. Tello Valverde CP, Ebrahimi G, Sprangers MA, Pateras K, Bruynzeel AME, Jacobs M, et al. Impact of Short-Course Palliative Radiation Therapy on Pancreatic Cancer-Related Pain: Prospective Phase 2 Nonrandomized PAINPANC Trial. International Journal of Radiation Oncology, Biology, Physics. 2024;118(2):352-61. [Crossref]  [PubMed]
  39. Buwenge M, Arcelli A, Cellini F, Deodato F, Macchia G, Cilla S, et al. Pain Relief after Stereotactic Radiotherapy of Pancreatic Adenocarcinoma: An Updated Systematic Review. Current Oncology. 2022;29(4):2616-29. [Crossref]  [PubMed]  [PMC]
  40. Hammer L, Hausner D, Ben-Ayun M, Shacham-Shmueli E, Morag O, Margalit O, et al. Single-Fraction Celiac Plexus Radiosurgery: A Preliminary Proof-of-Concept Phase 2 Clinical Trial. International Journal of Radiation Oncology, biology, Physics. 2022;113(3):588-93. [Crossref]  [PubMed]
  41. Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. The British Journal of Surgery. 2005;92(5):615-23. [Crossref]  [PubMed]
  42. Myint AS, Gerard JP. Role of radiotherapy in the treatment of rectal cancer in older patients. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2020;46(3):349-57. [Crossref]  [PubMed]
  43. Stewart AJ, Van Limbergen EJ, Gerard JP, Appelt AL, Verhaegen F, Berbee M, et al. GEC ESTRO ACROP consensus recommendations for contact brachytherapy for rectal cancer. Clinical and translational radiation oncology. 2022;33:15-22. [Crossref]  [PubMed]  [PMC]
  44. Ketelaers SHJ, Jacobs A, Verrijssen AE, Cnossen JS, van Hellemond IEG, Creemers GM, et al. A Multidisciplinary Approach for the Personalised Non-Operative Management of Elderly and Frail Rectal Cancer Patients Unable to Undergo TME Surgery. Cancers. 2022;14(10). [Crossref]  [PubMed]  [PMC]
  45. De Felice F, Crocetti D, Maiuri V, Parisi M, Marampon F, Izzo L, et al. Locally Advanced Rectal Cancer: Treatment Approach in Elderly Patients. Current Treatment Options in Oncology. 2020;21(1):1. [Crossref]  [PubMed]
  46. Wang SJ, Hathout L, Malhotra U, Maloney-Patel N, Kilic S, Poplin E, et al. Decision-Making Strategy for Rectal Cancer Management Using Radiation Therapy for Elderly or Comorbid Patients. International Journal of Radiation oncology, Biology, Physics. 2018;100(4):926-44. [Crossref]  [PubMed]  [PMC]
  47. Hathout L, Maloney-Patel N, Malhotra U, Wang SJ, Chokhavatia S, Dalal I, et al. Management of locally advanced rectal cancer in the elderly: a critical review and algorithm. Journal of Gastrointestinal Oncology. 2018;9(2):363-76. [Crossref]  [PubMed]  [PMC]
  48. Francois E, De Bari B, Ronchin P, Nouhaud E, Martel-Lafay I, Artru P, et al. Comparison of short-course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial. European journal of cancer. 2023;180:62-70. [Crossref]  [PubMed]
  49. Francois E, Magne N, Boulahssass R, Ronchin P, Huguenet V, De Lavigerie B, et al. Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2024;193:110144. [Crossref]  [PubMed]
  50. Neelis KJ, Kip DM, Speetjens FM, van der Linden YM. Treatment results for patients with squamous-cell carcinoma of the anus, a single institution retrospective analysis. Radiation oncology. 2022;17(1):81. [Crossref]  [PubMed]  [PMC]
  51. Geltzeiler CB, Tsikitis VL, Kim JS, Thomas CR Jr, Herzig DO, Lu KC. Variation in the Use of Chemoradiotherapy for Stage II and III Anal Cancer: Analysis of the National Cancer Data Base. Annals of Surgical Oncology. 2016;23(12):3934-40. [Crossref]  [PubMed]
  52. Fallai C, Perrotta A, Valvo F, Badii D, Olmi P. Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Critical Reviews in Oncology/Hematology. 2007;61(3):261-8. [Crossref]  [PubMed]
  53. Gouriou C, Lemanski C, Pommier P, Le Malicot K, Saint A, Rivin Del Campo E, et al. Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE. British Journal of Cancer. 2024;130(5):769-76. [Crossref]  [PubMed]
  54. Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M, Blomqvist C. Chemoradiotherapy of anal cancer is feasible in elderly patients: treatment results of mitomycin-5-FU combined with radiotherapy at Helsinki University Central Hospital 1992-2003. Acta Oncologica. 2006;45(6):736-42. [Crossref]  [PubMed]
  55. Miller ED, Nalin AP, Diaz Pardo DA, Arnett AL, Huang E, Gasior AC, et al. Disparate Use of Chemoradiation in Elderly Patients With Localized Anal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN. 2021;20(6):644-52 e2. [Crossref]  [PubMed]
  56. Yamamoto M, Yamasaki M, Sugimoto K, et al. Risk evaluation of postoperative delirium using comprehensive geriatric assessment in elderly patients with esophageal cancer. World J Surg. 2016;40:2705-12. [Crossref]  [PubMed]
  57. Shimada R, Yamasaki M, Tanaka K, Makino T, Doki Y, Yamashita K. Changes in the quality of life score following preoperative chemotherapy in elderly patients with esophageal cancer. Esophagus. 2022;19:113-9. [Crossref]  [PubMed]
  58. Yu J, Zhang W, Wang C, Hu Y. The Prognostic Value of Pretreatment Geriatric Nutritional Risk Index in Esophageal Cancer: A Meta-Analysis. Nutr Cancer. 2022;74(9):3202-10. [Crossref]  [PubMed]
  59. Lund CM, Vistisen KK, Olsen AP, Bardal P, Schultz M, Dolin TG, et al. The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO). Br J Cancer. 2021;124:1949-58. [Crossref]  [PubMed]  [PMC]
  60. Güzelöz Z, Görken İB, Aydın B, Sert F, Yalman D, Parvizi M, et al. Evaluation of treatment outcomes and tolerability in older patients with rectal cancer treated with radiotherapy accompanied by the G-8 geriatric score: TROD13-003 multicenter study. J Geriatr Oncol. 2024;15(3):101739. [Crossref]  [PubMed]
  61. Pearce J, Swinson D, Cairns D, Nair S, Baxter M, Petty R, et al.; GO2 trial investigators. Frailty and treatment outcome in advanced gastro-oesophageal cancer: an exploratory analysis of the GO2 trial. J Geriatr Oncol. 2022;13:287-93. [Crossref]  [PubMed]  [PMC]
  62. Cao Y, Han D, Yang S, Shi Y, Zhao S, Jin Q, et al. Effects of pre-operative enteral immunonutrition for esophageal cancer patients treated with neoadjuvant chemoradiotherapy: protocol for a multicenter randomized controlled trial (point trial, pre-operative immunonutrition therapy). BMC Cancer. 2022;22(1):650. [Crossref]  [PubMed]  [PMC]
  63. Liposits G, Skuladottir H, Ryg J, et al. The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, dNLR, YKL-40, and IL-6) in vulnerable older patients with metastatic colorectal cancer receiving palliative chemotherapy randomized NORDIC9-study. J Clin Med. 2022;11:5603. [Crossref]  [PubMed]  [PMC]
  64. Lee SC, Huh JW, Lee WY, Yun SH, Kim HC, Cho YB, et al. Prognostic value of serum inflammatory markers in colorectal cancer. Int J Colorectal Dis. 2020;35:1211-9. [Crossref]  [PubMed]
  65. Takagi A, Hawke P, Tokuda S, Toda T, Higashizono K, Nagai E, et al. Serum carnitine as a biomarker of sarcopenia and nutritional status in preoperative gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle. 2022;13:287-95. [Crossref]  [PubMed]  [PMC]
  66. Güç ZG, Altay C, Özgül HA, Ellidokuz H, Yavuzşen T. GNRI, and count scores: simple predictors of sarcopenia in metastatic colorectal cancer patients. Support Care Cancer. 2022;30:7845-52. [Crossref]  [PubMed]
  67. Patel I, Winer A. Assessing Frailty in Gastrointestinal Cancer: Two Diseases in One? Curr Oncol Rep. 2024;26:90-102. [Crossref]  [PubMed]
  68. Sert F, Metcalfe E, Erkal E, Alço G, Bakkal H, Özyiğit G. Evaluation of the Radiation Oncologists' Awareness and Needs about Geriatric Oncology: TROD-13-001 Study. Turk J Oncol. 2023;38(3):295-300. [Crossref]